Abstract 641P
Background
Ecubectedin –PM14– (ECU) is a new chemical entity that forms DNA adducts that inhibit RNA synthesis and active transcription of protein-coding genes. Antitumor activity as single agent and combined with Irinotecan (IRI) has been shown in vitro and in vivo in mice bearing xenografted human-derived tumors.
Methods
Open-label, dose-escalating, phase 1/2 trial of ECU administered as a 3-hour infusion + IRI i.v. D1 q3wk in patients (pts) with selected advanced solid tumors, adequate organ function and ECOG PS score of 0-1. 1ry endpoint of phase 1 is to determine the maximum tolerated dose (MTD) and recommended dose (RD) of the combination, and of phase 2 is to confirm RD and evaluate efficacy (overall response rate, ORR) in selected tumor types.
Results
Phase 1: 30 pts were treated. Baseline characteristics: median age 60 years; female 70%; ECOG PS 0: 43%; median no. of prior lines (range): 4 (1-8). Most common tumor types: ovarian (n=7), NSCLC (n=5), STS (n=4). The MTD was ECU 4.5 mg/m2 + IRI 50 mg/m2 + 1ry GCSF prophylaxis D1 q3wk. The RD was ECU 4.5 mg/m2 + IRI 40 mg/m2 + 1ry GCSF prophylaxis D1 q3wk (dose-limiting toxicities [DLTs] at RD: G3 febrile neutropenia/ vomiting/ diarrhea in one pt, and G3 vomiting in another pt). Main treatment-related or unknown adverse events at the RD (n=15) were fatigue (80%), nausea (60%) and decreased appetite (33%). Main grade 3/4 lab abnormalities were transaminase increase (40%) and neutropenia (27%) -11 pts received 1ry GCSF prophylaxis-. Only one pt (7%) had febrile neutropenia (without 1ry GCSF prophylaxis). Antitumor activity comprised stable disease ≥4 months in 9 pts (30%) at all dose levels, mainly in NSCLC. Mean (CV%) plasma clearance of ECU was 4.9 L/h [56%]. PK parameters of IRI and SN-38 were similar to previously reported values. Phase 2 is ongoing, and only recruiting NSCLC patients. At cutoff, 9 pts have been treated. Safety and efficacy data of this cohort will be updated at the meeting.
Conclusions
At the RD, ECU + IRI + 1ry GCSF prophylaxis has a manageable safety profile. Hematological abnormalities, fatigue, transaminase increase and nausea were the main toxicities. No major PK drug-drug interactions between ECU and IRI were found.
Clinical trial identification
EudraCT 2021-000415-23.
Editorial acknowledgement
Legal entity responsible for the study
PharmaMar S.A.
Funding
PharmaMar S.A.
Disclosure
A. Gil Torralvo: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Pfizer, Novartis, Daiichi Sankyo. M. Vieito: Financial Interests, Personal, Invited Speaker: Novocure; Financial Interests, Personal, Other, Steering committee member: BMS; Non-Financial Interests, Principal Investigator: Roche, BMS, Taiho, Hutchinson Pharma, Novartis, Mundipharma, Enterome, Debiopharm. G.F. Boggio, C. Kahatt, S. Fudio, A. Nieto: Financial Interests, Personal, Full or part-time Employment: PharmaMar; Financial Interests, Personal, Stocks/Shares: PharmaMar. C.M. Fernandéz, A. Hernandez, E. Cristoveanu: Financial Interests, Personal, Full or part-time Employment: PharmaMar. A. Redondo: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, GSK, PharmaMar, Pharma&; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, GSK, PharmaMar, Boehringer Ingelheim; Financial Interests, Institutional, Local PI: Roche, Eisai, PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01